Category Medicine and Healthcare
Press Release
MobilityWorks Opens 100th Location, Furthering Its Mission to Provide Accessible Mobility Solutions Nationwide
MobilityWorks® announces its expansion to 100 locations across 37 states, furthering its mission to provide wheelchair users with the mobility, independence and personal freedom they desire. Read More
Press Release
U.S. News & World Report Ranks John Theurer Cancer Center as the #1 Cancer Program in NJ and the Only Top 50 Cancer Program in the State
Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program in New Jersey by U.S. News and World Report Read More
Press Release
Jaguar Health Reports Second Quarter 2024 Financial Results
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results Jaguar planning to begin commercial launch in October 2024 for Gelclair®, the company's third prescription product Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast Read More
Press Release
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024 Read More
Press Release
Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration
Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System Strategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally Read More
Press Release
R1 RCM Named Top Performing Revenue Cycle Management Outsourcing Provider by 2024 Black Book Health Systems Client Survey
Managed services customers validated highest client satisfaction ratings on R1 RCM, a major player in the medical financial services industry that is working with 95 of the top 100 U.S. health systems and managing over $55 billion in net patient revenue. Read More
Press Release
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devices All-stock licensing structure aligns the licensor's long-term interest with Ainos shareholders' Read More
Press Release
Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested Read More
Press Release
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - Dermata continues discussions with potential botulinum toxin partners for DMT410 - Raised $2.3 million in net proceeds from financing completed in 2Q 2024 Read More
Press Release
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful Results
In 2022 breast cancer was the most common cancer in women in 157 countries out of 185, and lung cancer is the most common cancer worldwide.1 Click here to register for webcast. Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi of crofelemer in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure Read More
Press Release
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky is also an advisor to Magdalena Biosciences, the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced, Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for development with potential corporate partners; the global schizophrenia treatment market valued at $8.29 billion Read More
Press Release